BioCryst Pharma (BCRX) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.34 +5.08%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
CPHC, ROLR, EROC, More
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
CPHC, ROLR, EROC, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $81 million versus the consensus estimate of $81.41 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
- Sanara MedTech Inc. (SMTI) Misses Q2 EPS by 2c
- Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 45c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
